- Analyse du marché pharmaceutique officine et hôpital : impact Covid-19, recours aux génériques, biosimilaires, hybrides, taux de pénétration, produits innovants, médicaments onéreux, simulation de la clause de sauvegarde, articles de la LFSS, poids de la régulation- Création d’un outil de mesure d’impact des baisses de prix des médicaments à destination des laboratoires, du CEPS et du LEEM (économie prévue 2024 : 850 M€)- Réalisation d’études sur la consommation de produits de santé – oncologie, anticorps monoclonaux, vaccins, antalgiques, automédication - pour les autorités de santé CEPS, DSS, IGAS, DASS et l’industrie- Construction d'infographies sur des marchés de santé spécifique de médicaments et dispositifs médicaux : épilepsie, hypertension, hépatite, diabète...#healthdata #pharma #marketaccess #pricing

Co-developped SaaS tools (pharma procurement gains and product catalog) for hospital usersLed a working group : suppliers, hospitals, pharmacists, digital developpersDefined pilot and national marketing actionsSimulated business models for 3 years, contract drafting with lawyers and sales force briefFollowed-up clients : hotline support, discount for new offers, needs collection for improvement

Controlled expenses and use of cholesterol-lowering drugs (statins and PCSK9 inhibitors)Defined iatrogenic prevention tools for GPs prescription securing

Wrote technical and economic dossiers for medical devices reimbursement for French evaluation submissionLed strategic studies for European markets (cardiology, pulmonology, neurology areas)

Tested new “All Inclusive” business models for surgery in private healthcare institutions to create a network- Benchmarked surgery costs for Public Health Insurance / Private Health Insurance / Patients in different French areas- Negotiated financial package with Private Health Insurance, clinics and surgeons/anesthetists taking into account shorter hospital stays and home rehabilitation care- Defined steps from marketing insured persons approach to health facilities and professional payment (mailing, flyers, call center, Internet apps)

Managed urology projects for international marketing with R&D, clinicians, regulatory affairs, KOLs. International forecasts establishing for B.Braun subsidiaries (UK, Germany, France, Italy, Netherlands)- Explored markets for a digital diuresis module for ICU, wrote product specification and met providers. Environment analysis : Technologies / Products / Competitors.- Updated IFU and packaging for hospital and out-patient market products for a global launch. Adaptation to the particularities of each country.- Participation in the preparation of congress and implementation of promotional materials.

Defined a new production and supply-chain strategy for a better cost/quality ratio- Successfully improved antiseptic Dakin process using a complete factorial design.- Implemented corrective actions approved by the Industrial Division.- Managed customers complaints and investigated causes with Insurance Quality.

Measured Mycophenolate Mofetil (Cellcept®) plasma level in patients with autoimmune disease - Used HPLC-MS method and established pharmacokinetic-pharmacodynamic relationships- Carried out extensive research in international medicine publications- Planned analytical experiments to personalize treatments

Controlled quality of raw materials, finished goods with European Pharmacopoeia references.Wrote infrared spectrometer's procedure for technicians' good pratice.